<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884503</url>
  </required_header>
  <id_info>
    <org_study_id>Kb668/2018</org_study_id>
    <nct_id>NCT04884503</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome</brief_title>
  <official_title>Assessment of the Effectiveness of the Selected Treatment Method and Psychological Disorders of Primary Burning Mouth Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wroclaw Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The burning mouth syndrome (BMS) is a chronic pain syndrome of the oral mucosa. Feels like&#xD;
      experiencing a burning sensation, pain, stinging, or numbness in the mouth along with a&#xD;
      feeling of dryness, paraesthesia, taste disturbance or hypersensitivity.The complaints are&#xD;
      usually bilateral, of moderate intensity, they persist for a minimum of 4-6 months and&#xD;
      concern the clinically unchanged membrane mucous.The psychiatric aspect of BMS is very&#xD;
      important. The presence of BMS has been shown to be associated with depression, increased&#xD;
      anxiety levels, hypochondria, and carcinophobia and emotional instability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The burning mouth syndrome (BMS) is a chronic pain syndrome of the oral mucosa. Patients have&#xD;
      experiencing a burning sensation, pain, stinging, or numbness in the mouth along with a&#xD;
      feeling of dryness, paraesthesia, taste disturbance or hypersensitivity. The complaints are&#xD;
      usually bilateral, of moderate intensity, they persist for a minimum of 4-6 months and&#xD;
      concern the clinically unchanged membrane mucous.The psychiatric aspect of BMS is very&#xD;
      important. The presence of BMS has been shown to be associated with depression, increased&#xD;
      anxiety levels, hypochondria, and carcinophobia and emotional instability&#xD;
&#xD;
      The first step is to determine the specific type of BMS, i.e. to exclude a causal&#xD;
      relationship with the existing local factors, general diseases and medications taken.&#xD;
&#xD;
      The pathophysiology of Primary Burning Mouth Syndrome is unclear. Due to the lack of&#xD;
      morphological changes in the oral cavity with the simultaneous occurrence of troublesome pain&#xD;
      symptoms, it is now assumed that pain in BMS has a neuropathic mechanism.&#xD;
&#xD;
      Among the psychotropic drugs, the most commonly used in the treatment of BMS was clonazepam,&#xD;
      a drug with anticonvulsant and anxiolytic properties .&#xD;
&#xD;
      In this study, the investigators used clonazepam because of which it has proven effectiveness&#xD;
      in therapy in combination with a tongue protector made for the purpose of the test. Use of a&#xD;
      tongue protector in the form of a bag put on it 3 times a day is relatively new method of&#xD;
      treatment, which is to exclude the detachment of the tongue's para-function on burning.&#xD;
&#xD;
      60 patients were qualified for the study, of which 57 patients, including 34 women and 23&#xD;
      men, aged 47-77 years, took part in the program.&#xD;
&#xD;
      Pain assessment The symptoms of pain intensity BMS were assessed using the VAS (Visual Analog&#xD;
      Scale) The duration of burning was also assessed, the type of burning according to Levis, the&#xD;
      occurrence of taste disturbances and their determination, subjective feeling of dry mouth,&#xD;
      place of burning sensation: tongue, palate, lips, mucosa of the mouth vestibule with gums,&#xD;
      cheek mucosa The psychologist cooperating in the project conducted and then interpreted four&#xD;
      psychological tests: STAI (state and trait anxiety inventory) and the Beck Anxiety Scale BAI&#xD;
      and the Beck Depression Scale BDI. Moreover, the WHOQOL quality of life test was carried out&#xD;
      - according to WHO&#xD;
&#xD;
      A follow-up examination was performed on the day of treatment completion and 3 months later&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2019</start_date>
  <completion_date type="Actual">September 6, 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of pain</measure>
    <time_frame>1 month and 3 months after therapy</time_frame>
    <description>combining the use of clonazepam versus the group wearing a tongue protector Tongue protector was use in order to exclude occlusal parafunction. VAS (visual analog scale) was use to asses pain score before and after therapy&#xD;
scale from 0 to 10 0 no pain 10 maximum pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the depression patients diagnosed with BMS.</measure>
    <time_frame>1 month and 3 months after therapy</time_frame>
    <description>Assessment depression Beck depresion scale Questionnaire&#xD;
scale from 0 to 28 0 no deppresion 28 depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the sleepiness patients diagnosed with BMS.</measure>
    <time_frame>1 month and 3 months after therapy</time_frame>
    <description>assessment of side effects when taking clonazepam such as sleepiness was assessed on the basis of surveys with patients: Athenian Insomnia Scale Questionnaire&#xD;
scale from 0 to 24&#xD;
0 no sleep disorders 24 insomnia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>assessment of side effects : slowness</measure>
    <time_frame>1 month and 3 months after therapy</time_frame>
    <description>assessment of side effects when taking clonazepam such as dry mouth, slowness, was assessed on the basis of surveys with patients</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Burning Mouth Syndrome</condition>
  <condition>Glossodynia</condition>
  <arm_group>
    <arm_group_label>Patients diagnosed with BMS traeting with Clonazepam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients diagnosed with BMS treating with tongue pads</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients wearing tongue pads 3 times a day for 20 minutes for 4 weeks to exclude parafunctions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonazepam tablets</intervention_name>
    <description>Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)</description>
    <arm_group_label>Patients diagnosed with BMS traeting with Clonazepam</arm_group_label>
    <other_name>patients treating with clonazepam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tongue pads</intervention_name>
    <description>wearing a tongue pad 3 times a day for 20 minutes for 4 weeks</description>
    <arm_group_label>Patients diagnosed with BMS treating with tongue pads</arm_group_label>
    <other_name>patients treating with tonque pads</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of BMS for at least 6 months&#xD;
&#xD;
          -  no clinical changes in the oral cavity that are clinically verifiable and may affect&#xD;
             symptoms,&#xD;
&#xD;
          -  no previous BMS therapy&#xD;
&#xD;
          -  age over 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  V and VII nerve neuralgia&#xD;
&#xD;
          -  patients with uncontrolled diabetes mellitus,&#xD;
&#xD;
          -  thyroid disease, anemia,&#xD;
&#xD;
          -  Sjogren's disease and&#xD;
&#xD;
          -  connective tissue disease (fibromyalgia),&#xD;
&#xD;
          -  patients after prior surgical / neurosurgical treatment of the head,&#xD;
&#xD;
          -  oncological treatment (radiotherapy),&#xD;
&#xD;
          -  pregnant women,&#xD;
&#xD;
          -  the occurrence of clinical pathologies in the oral cavity that may cause pain,&#xD;
&#xD;
          -  deficiencies of vitamin B12, folic acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>tomasz konopka, prof</last_name>
    <role>Study Director</role>
    <affiliation>Wroclaw Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacek Zborowski</name>
      <address>
        <city>Wroc≈Çaw</city>
        <state>Dolnoslaskie</state>
        <zip>52-311</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS, , clonazepam, BMS psychological disturbance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burning Mouth Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

